Propanc Biopharma Provides Shareholder Update

Rhea-AI Summary

Propanc Biopharma (Nasdaq: PPCB) provided a shareholder update on Jan 13, 2026 outlining 2025 progress and 2026 plans. The company said it will advance lead candidate PRP into a Phase 1b First‑In‑Human study in ~30–40 patients with advanced solid tumors at Peter MacCallum Cancer Centre in 2026. Propanc reported it raised $4 million after up‑listing to Nasdaq to fund clinical preparations, has invested over $30 million since inception, and holds an IP portfolio of 90+ issued patents. The update also described preclinical work on a synthetic backup Rec‑PRP and research into PRP for fibrosis, with key clinical manufacturing and PK method milestones expected by Q3 2026.

Positive

• Phase 1b trial planned for ~30–40 patients in 2026
• Raised $4 million to fund clinical preparation activities
• Intellectual property portfolio of 90+ issued patents
• Rec‑PRP synthetic backup designed for room‑temperature stability

Negative

• Clinical milestones and PK validation are planned and targeted for Q3 2026 (not completed)
• Share price volatility prompted recent shareholder enquiries after Nasdaq listing

News Market Reaction

-4.33%

1 alert

-4.33% News Effect

On the day this news was published, PPCB declined 4.33%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phase 1b sample size: 30–40 patients Cumulative PRP investment: Over $30 million Capital raised: $4 million +3 more

6 metrics

Phase 1b sample size 30–40 patients Planned First-In-Human study in advanced solid tumors

Cumulative PRP investment Over $30 million Total invested in PRP research and development to date

Capital raised $4 million Raised following up-listing to Nasdaq

Issued patents Over 90 patents Intellectual property portfolio related to proenzyme therapy

New patent applications Three applications Recently filed patents entering national phase

Peer-reviewed publications Fifth publication Recent acceptance in Scientific Reports journal

Market Reality Check

Price: $0.3135 Vol: Volume 58,030 is at 0.72x...

normal vol

$0.3135 Last Close

Volume Volume 58,030 is at 0.72x the 20-day average of 80,169, indicating subdued trading ahead of this update. normal

Technical Shares at $0.4531 are trading below the 200-day MA of $4.43 and sit 98.11% below the 52-week high, hovering near the 52-week low.

Peers on Argus

PPCB fell 1.97% while peers AKTX, LIXT, ALLR, and BOLD declined between 4.2% and...

PPCB fell 1.97% while peers AKTX, LIXT, ALLR, and BOLD declined between 4.2% and 6.77%, suggesting today’s weakness aligns with broader biotech pressure rather than a PPCB-specific move.

Historical Context

5 past events · Latest: Dec 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 22	Scientific publication	Positive	-8.4%	Peer‑reviewed PRP data in PDAC fibroblasts and Phase 1b planning.
Dec 04	Research collaboration	Positive	-4.3%	Mesenchymal drift research and PRP Phase 1b preparation for 2026.
Dec 01	IP and fibrosis update	Positive	+5.5%	Foreign filing license and patents for cancer and fibrosis uses of PRP.
Nov 17	Earnings & corporate	Positive	-2.8%	Q1 results, PRP manufacturing progress, Rec‑PRP preclinical, financings.
Nov 10	Large private placement	Positive	-12.4%	Up to $100M Series C preferred deal and warrants with PRP FIH timeline.

Pattern Detected

Recent positive-sounding scientific and financing updates have often been followed by negative next-day price reactions, indicating a pattern of selling into news.

Recent Company History

Over the last few months, Propanc has focused on advancing PRP toward a Phase 1b study in 2026, expanding IP around cancer and fibrosis, and securing financing via an underwritten offering and a private placement of up to $100M. Despite these seemingly positive milestones, four of the last five news events saw negative 24-hour price moves, with only the Dec 1 patent-related fibrosis update posting a 5.47% gain. Today’s optimistic 2026 clinical roadmap continues this strategic trajectory.

Market Pulse Summary

This announcement describes substantial 2025 groundwork and plans to start a Phase 1b First‑In‑Human...

Analysis

This announcement describes substantial 2025 groundwork and plans to start a Phase 1b First‑In‑Human study in 30–40 advanced cancer patients in 2026, supported by more than $30 million invested in PRP and a portfolio of over 90 patents. It follows recent financings and regulatory filings that highlight liquidity needs and going‑concern risk. Investors may focus on execution milestones for the planned trial, further peer‑reviewed data, and future financing terms as key markers of progress.

Key Terms

phase 1b, first-in-human (fih), pharmacokinetics, fibrosis, +1 more

5 terms

phase 1b medical

"In 2026, we plan to advance PRP into a Phase 1b First-In-Human..."

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

first-in-human (fih) medical

"advance PRP into a Phase 1b First-In-Human (FIH) clinical study..."

The first-in-human (FIH) designation marks the first time a new drug, vaccine, medical device, or treatment is given to people rather than tested only in labs or animals. For investors, FIH is a major milestone because it moves a candidate from preclinical testing into human safety and early effectiveness evaluation—think of it as the prototype being driven on public roads, where results strongly influence future development costs, timelines, and commercial potential.

pharmacokinetics medical

"bioanalytical method to measure PRP levels... over time (pharmacokinetics)"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

fibrosis medical

"potential of PRP for the treatment of fibrosis—an area representing..."

Fibrosis is the process where excess scar tissue forms in an organ or tissue, often as a response to injury or long-term damage. This buildup can impair normal function, much like thickening insulation reduces the effectiveness of a wire. For investors, fibrosis is significant because it can signal ongoing health issues that may lead to increased medical costs or influence a company’s performance in healthcare-related sectors.

peer-reviewed technical

"our fifth peer-reviewed scientific publication was recently accepted..."

Peer-reviewed means a study, report or paper has been examined and approved by independent experts in the same field before publication, like having multiple qualified inspectors check a building plan. For investors, peer review signals that methods and conclusions have passed scrutiny beyond the author’s claims, making scientific, clinical or technical findings more reliable and reducing the chance that decisions or valuation are based on unchecked or flawed evidence.

AI-generated analysis. Not financial advice.

CEO Highlights Significant Progress Achieved & Outlines Ambitious Plans for 2026

MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced a shareholder update from its Chief Executive Officer and Cofounder, Mr. James Nathanielsz.

In this update, Mr. Nathanielsz highlights the significant progress achieved during 2025 and outlines the Company’s ambitious plans for 2026. With strong confidence, Propanc is executing its strategic roadmap for the clinical development of its lead asset, PRP, while further strengthening its scientific platform by expanding into additional therapeutic areas with high unmet medical need and advancing its pipeline, including the development of a fully synthetic backup compound, Rec-PRP.

Dear Shareholder,

I am delighted to share an update on our recent achievements and to outline our exciting outlook for 2026. The substantial groundwork completed over the past year has positioned the Company for meaningful growth as we focus on advancing our lead clinical asset, PRP.

PRP is a fixed-dose combination of pancreatic proenzymes trypsinogen and chymotrypsinogen. In 2026, we plan to advance PRP into a Phase 1b First-In-Human (FIH) clinical study involving approximately 30–40 patients with advanced solid tumors who have exhausted available treatment options. This important study is expected to be conducted at the Peter MacCallum Cancer Centre in Melbourne, Australia—Australia’s largest and most prestigious cancer hospital.

Our management and R&D teams enter this next phase of development with a high level of confidence. Over many years, we have conducted extensive research to build a compelling scientific rationale supporting PRP’s potential to make a meaningful difference for late-stage cancer patients. Notably, the therapeutic use of proenzymes in cancer has a history spanning more than 100 years. Professor John Beard of the University of Edinburgh first proposed the use of trypsin injections in cancer patients, with reports of remarkable outcomes documented in respected medical journals at the turn of the 20th century, including the Journal of the American Medical Association and Medical Record (NY).

Since inception, Propanc has invested over $30 million to rediscover, refine, and rigorously investigate PRP as a modern cancer therapy. Our research suggests that PRP selectively targets cancer cells while leaving healthy cells unaffected, resulting in no severe or serious treatment-related side effects observed to date. While we hold strong conviction in the therapy’s potential based on the accumulated evidence, our responsibility is to advance PRP through a carefully designed, efficient, and robust clinical program that prioritizes patient safety and maximizes the likelihood of success.

Over the past year, we have built a strong foundation for the road ahead. Following our up-listing to Nasdaq, we raised $4 million, enabling us to initiate critical clinical preparation activities. These include manufacturing PRP for the upcoming clinical trial, validating a bioanalytical method to measure PRP levels in patients’ blood over time (pharmacokinetics), and preparing the clinical trial application for ethics committee submission at Peter MacCallum Cancer Center. We expect these activities to be completed during the third quarter of this calendar year, and we look forward to providing further updates as milestones are achieved.

Beyond PRP, we continue to strengthen our scientific base through longstanding research collaborations with the Universities of Jaén and Granada. After more than a decade of dedicated research, we continue to publish and patent discoveries related to the use of proenzymes as a novel approach to treating metastatic cancer. Our intellectual property portfolio now includes over 90 issued patents, with further growth expected as three recently filed patent applications enter national phase across multiple jurisdictions worldwide. We are also pleased to report that our fifth peer-reviewed scientific publication was recently accepted in Scientific Reports, an online journal from the Nature portfolio.

Importantly, we are expanding our research into additional therapeutic indications with significant unmet medical needs. Last month, we announced ongoing investigations into the potential of PRP for the treatment of fibrosis—an area representing a multi-billion-dollar market and a serious global health burden.

In parallel, we are advancing our preclinical program for Rec-PRP, a world-first, fully synthetic recombinant version of our lead product. Rec-PRP is designed to enhance efficacy and improve room-temperature stability, supporting our long-term vision of global access to proenzyme-based therapies, particularly in regions where cold-chain logistics may be challenging. Both PRP and Rec-PRP are expected to be administered via periodic injections and based on their favorable safety profiles, are unlikely to require hospital admission. We also believe they have the potential to be significantly more cost-effective due to scalable manufacturing and ease of administration.

Finally, we acknowledge the recent shareholder enquiries regarding our share price performance following our Nasdaq listing. Short-term market and trading dynamics can influence share price movements; however, our focus remains firmly on executing our long-term strategy and delivering meaningful clinical and scientific progress. We are confident that the year ahead holds substantial opportunity for value creation and are excited about what lies ahead.

Thank you for your continued support. We look forward to keeping you informed as we progress on this important journey.

Yours faithfully,
Mr. James Nathanielsz, BAS, MEI (SUT)
Chief Executive Officer & Cofounder
Propanc Biopharma, Inc.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

FAQ

What clinical study does Propanc Biopharma (PPCB) plan in 2026?

Propanc plans a Phase 1b First‑In‑Human study of PRP in approximately 30–40 advanced solid tumor patients in 2026.

How much funding did Propanc (PPCB) raise after its Nasdaq up‑listing?

The company reported it raised $4 million following its Nasdaq up‑listing to support clinical preparation.

What is Rec‑PRP and why is it important for PPCB shareholders?

Rec‑PRP is a fully synthetic recombinant backup to PRP designed to enhance efficacy and enable room‑temperature stability for broader distribution.

When does Propanc expect to complete manufacturing and PK method validation for PRP?

The company expects manufacturing and bioanalytical PK method validation to be completed during Q3 2026.

How large is Propanc’s patent portfolio reported on Jan 13, 2026?

Propanc reported an intellectual property portfolio comprising over 90 issued patents with additional applications entering national phase.